Frontline ponatinib plus hyper-CVAD over imatinib in adults with Ph-positive acute lymphoblastic leukemia: realworld efficacy and risks of early ponatinib dose reduction.

Haematologica · 2026 · PMC13317847 · PMID 41609055

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

33.1%) and showed a trend toward better overall survival (OS).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.